RT Journal Article
SR Electronic
T1 SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.12.21251659
DO 10.1101/2021.02.12.21251659
A1 Nash, Denis
A1 Rane, Madhura S.
A1 Chang, Mindy
A1 Kulkarni, Sarah Gorrell
A1 Zimba, Rebecca
A1 You, William
A1 Berry, Amanda
A1 Mirzayi, Chloe
A1 Kochhar, Shivani
A1 Maroko, Andrew
A1 Robertson, McKaylee M.
A1 Westmoreland, Drew A.
A1 Parcesepe, Angela M.
A1 Waldron, Levi
A1 Grov, Christian
YR 2021
UL http://medrxiv.org/content/early/2021/10/12/2021.02.12.21251659.abstract
AB Background Epidemiologic risk factors for incident SARS-CoV-2 infection as determined via prospective cohort studies greatly augment and complement information from case-based surveillance and cross-sectional seroprevalence surveys.Methods We estimated the incidence of SARS-CoV-2 infection and risk factors in a well-characterized, national prospective cohort of 6,738 U.S. adults, enrolled March-August 2020, a subset of whom (n=4,510) underwent repeat serologic testing between May 2020 and January 2021. We examined the crude associations of sociodemographic factors, epidemiologic risk factors, and county-level community transmission with the incidence of seroconversion. In multivariable Poisson models we examined the association of social distancing and a composite score of several epidemiologic risk factors with the rate of seroconversion.Findings Among the 4,510 individuals with at least one serologic test, 323 (7.3%, 95% confidence interval [CI] 6.5%-8.1%) seroconverted by January 2021. Among 3,422 participants seronegative in May-September 2020 and tested during November 2020-January 2021, we observed 161 seroconversions over 1,646 person-years of follow-up (incidence rate of 9.8 per 100 person-years [95%CI 8.3-11.5]). In adjusted models, participants who reported always or sometimes social distancing with people they knew (IRRalways vs. never 0.43, 95%CI 0.21-1.0; IRRsometimes vs. never 0.47, 95%CI 0.22-1.2) and people they did not know (IRRalways vs. never 0.64, 95%CI 0.39-1.1; IRRsometimes vs. never 0.60, 95%CI 0.38-0.97) had lower rates of seroconversion. The rate of seroconversion increased across tertiles of the composite score of epidemiologic risk (IRRmedium vs. low 1.5, 95%CI 0.92-2.4; IRRhigh vs. low 3.0, 95%CI 2.0-4.6). Among the 161 observed seroconversions, 28% reported no symptoms of COVID-like illness (i.e., were asymptomatic), and 27% reported a positive SARS-CoV-2 diagnostic test. Ultimately, only 29% reported isolating and 19% were asked about contacts.Interpretation Modifiable epidemiologic risk factors and poor reach of public health strategies drove SARS-CoV-2 transmission across the U.S during May 2020-January 2021.Funding U.S. National Institutes of Allergy and Infectious Diseases (NIAID).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot an intervention studyClinical Protocols https://bmjopen.bmj.com/content/11/9/e048778 Funding StatementFunding for this project is provided by The National Institute of Allergy and Infectious Diseases (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy, and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina Population Center).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY) Graduate School for Public Health and Health Policy.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, [DN]. The data are not yet publicly available, but we are preparing to post a deidentified, HIPAA compliant, public use version of our baseline and follow-up data on GitHub. https://cunyisph.org/chasing-covid/